(S)-Nipecotic Acid

(S)-Nipecotic Acid

SCHEMBL254683

O=C(O)[C@H]1CCCNC1

nearest known ligand 0.00

Full drug profile on Sugi Atlas →

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 790 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4745152-A2 PEPTIDES BINDING TO BFL-1 Dana-Farber Cancer Institute, Inc. (US) 2026-05-20 EP claimed
EP-3341008-B1 PEPTIDES BINDING TO BFL-1 DANA FARBER CANCER INST INC (US) 2026-04-15 EP claimed
US-12600825-B2 Polymer compositions and biosurfaces comprising them on sensors ZEPTO LIFE TECHNOLOGY, INC. (US) 2026-04-14 US claimed
US-20260014274-A1 REVERSIBLE, COVALENT POLYNUCLEOTIDE CONDENSATION APPROACH FOR ENHANCED GENE DELIVERY UNIV TEXAS (US) 2026-01-15 US claimed
US-20250277012-A1 CONJUGATED HEPCIDIN MIMETICS PROTAGONIST THERAPEUTICS, INC. 2025-09-04 US claimed
US-20240226225-A1 CONJUGATED HEPCIDIN MIMETICS PROTAGONIST THERAPEUTICS, INC. (US) 2024-07-11 US claimed
US-20240209053-A1 CONJUGATED HEPCIDIN MIMETICS PROTAGONIST THERAPEUTICS, INC. (US) 2024-06-27 US claimed
WO-2024128640-A1 CATALYST FOR HYDROGENATION AND DEHYDROGENATION, METHOD FOR PRODUCING SAME, AND HYDROGENATION AND DEHYDROGENATION REACTION METHOD USING SAME 울산과학기술원 2024-06-20 WO claimed
US-11970592-B2 Window cover film and flexible display panel including the same SK INNOVATION CO., LTD. (KR) 2024-04-30 US claimed
CN-117813313-A Binding hepcidin mimetics 领导医疗有限公司 2024-04-02 CN claimed
WO-2013139697-A1 CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS POLYPHOR AG (CH) 2013-09-26 WO claimed
EP-2473502-A1 HETEROARYL COMPOUNDS AS KINASE INHIBITORS Novartis AG (CH) 2012-07-11 EP claimed
US-20120157433-A1 Heteroaryl Compounds as Kinase Inhibitors PFISTER KEITH B (US) 2012-06-21 US claimed
CN-102498107-A Heteroaryl compounds as kinase inhibitors NOVARTIS AG 2012-06-13 CN claimed
EP-2068878-A2 RHO KINASE INHIBITORS Boehringer Ingelheim International GmbH (DE) 2009-06-17 EP claimed
US-20080161297-A1 e.g. N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-dimethylamino-2-phenyl-acetamide; hypertension, atherosclerosis, restenosis, stroke, heart failure, coronary vasospasm, cerebral vasospasm, ischemia/reperfusion injury, pulmonary hypertension, angina, myocardial infarction, ALCON INC. (CH) 2008-07-03 US claimed
EP-1932852-A1 Novel taxane related peptides and uses thereof Campiani, Giuseppe (IT) 2008-06-18 EP claimed
WO-2008036540-A2 RHO KINASE INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2008-03-27 WO claimed
US-20070185128-A1 Compounds and compositions for treating obesity NOVO NORDISK A/S (DK) 2007-08-09 US claimed
WO-2006071079-A1 QUINAZOLINE DERIVATIVES FOR INHIBITING CANCER CELL GROWTH AND METHOD FOR THE PREPARATION THEREOF HANMI PHARM. CO., LTD. (KR) 2006-07-06 WO claimed